Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin.

TitleImmune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin.
Publication TypeJournal Article
Year of Publication2013
AuthorsBurns, JC, Song, Y, Bujold, M, Shimizu, C, Kanegaye, JT, Tremoulet, AH, Franco, A
JournalClin Exp Immunol
Date Published2013 Jul 31
iDASH CategoryKawasaki Disease (DBP1 & DBP4)
AbstractOBJECTIVES: The expansion of regulatory T cells (Treg) controls inflammation in children with acute Kawasaki disease (KD). Blockade of tumor necrosis factor (TNF)α is an emerging therapy for KD patients with refractory inflammation, but there is concern that this therapy could impede the host immune regulation. To define the effect of TNFα blockade, we conducted ex -vivo immune-monitoring in KD subjects who participated in a randomized, double-blind, placebo-controlled clinical trial of the addition of infliximab to standard intravenous immunoglobulin (IVIG) therapy. STUDY DESIGN: We enumerated circulating myeloid and plasmocytoid DC, Treg, and memory T cells (Tmem) in 14 consecutive, unselected KD patients (7 treated with IVIG, 7 with IVIG + infliximab) at 3 time points: 1) acute phase prior to treatment, 2) sub-acute phase 3) convalescent phase. RESULTS: Myeloid DC (mDC), but not plasmacytoid DC (pDC), were numerous in the peripheral blood in acute KD subjects and decreased in the sub-acute phase in both IVIG- and IVIG + infliximab-treated groups. The co-stimulatory molecule for antigen presentation to T cells, CD86, decreased in mDC from acute to sub-acute time points in both treatment groups, but not in the single patient who developed coronary artery aneurysms. We also defined tolerogenic mDC that expand in the sub-acute phase of KD not impaired by infliximab treatment. Treg and Tmem expanded after treatment with no significant differences between the two groups. CONCLUSIONS: Treatment of KD patients with infliximab does not adversely affect generation of tolerogenic mDC or the development of T cell regulation and memory.
Alternate JournalClin. Exp. Immunol.
PubMed ID23901839